Flora Growth Corp (FLGC)

$1.36

-0.18

(-11.69%)▲

Market is closed - opens 7 PM, 29 Apr 2024

Insights on Flora Growth Corp

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 17.31M → 17.97M (in $), with an average increase of 3.7% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 1.23M → -8.28M (in $), with an average decrease of 769.8% per quarter

  • Vs NBIX

    In the last 1 year, Neurocrine Biosciences Inc. has given 34.1% return, outperforming this stock by 97.4%

Performance

  • $1.33
    $1.59
    $1.36
    downward going graph

    2.21%

    Downside

    Day's Volatility :16.59%

    Upside

    14.71%

    downward going graph
  • $0.63
    $5.48
    $1.36
    downward going graph

    53.68%

    Downside

    52 Weeks Volatility :88.5%

    Upside

    75.18%

    downward going graph

Returns

PeriodFlora Growth CorpSector (Consumer Staples)Index (Russel 2000)
3 Months
22.22%
4.3%
0.0%
6 Months
117.39%
12.2%
0.0%
1 Year
-63.33%
-0.6%
2.2%
3 Years
-98.39%
10.1%
-23.0%

Highlights

Market Capitalization
16.5M
Book Value
$0.72
Earnings Per Share (EPS)
-6.34
Wall Street Target Price
6.0
Profit Margin
-74.98%
Operating Margin TTM
-15.67%
Return On Assets TTM
-12.96%
Return On Equity TTM
-148.59%
Revenue TTM
76.1M
Revenue Per Share TTM
10.34
Quarterly Revenue Growth YOY
70.39999999999999%
Gross Profit TTM
2.4M
EBITDA
-8.4M
Diluted Eps TTM
-6.34
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.5
EPS Estimate Next Year
-0.2
EPS Estimate Current Quarter
-0.07
EPS Estimate Next Quarter
-0.05

Analyst Recommendation

Buy
    87%Buy
    12%Hold
    0
    0%Sell
Based on 8 Wall street analysts offering stock ratings for Flora Growth Corp(by analysts ranked 0 to 5 stars)
Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
7
7
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 341.18%

Current $1.36
Target $6.00

Company Financials

FY20Y/Y Change
Revenue
106.0K
-
Net Income
-14.3M
↑ 401.35%
Net Profit Margin
-13.5K%
-
FY21Y/Y Change
Revenue
9.0M
↑ 8371.7%
Net Income
-21.4M
↑ 49.81%
Net Profit Margin
-237.87%
↑ 13214.02%
FY22Y/Y Change
Revenue
37.2M
↑ 313.93%
Net Income
-52.6M
↑ 146.38%
Net Profit Margin
-141.59%
↑ 96.28%
FY23Y/Y Change
Revenue
76.1M
↑ 104.65%
Net Income
-53.9M
↑ 2.4%
Net Profit Margin
-70.85%
↑ 70.74%
Q3 FY22Q/Q Change
Revenue
10.8M
↑ 7.96%
Net Income
-7.4M
↓ 82.93%
Net Profit Margin
-68.35%
↑ 363.83%
Q4 FY22Q/Q Change
Revenue
11.5M
↑ 6.73%
Net Income
-12.5M
↑ 70.22%
Net Profit Margin
-109.02%
↓ 40.67%
Q1 FY23Q/Q Change
Revenue
20.1M
↑ 75.01%
Net Income
-3.9M
↓ 68.82%
Net Profit Margin
-19.42%
↑ 89.6%
Q2 FY23Q/Q Change
Revenue
21.5M
↑ 6.73%
Net Income
-44.6M
↑ 1041.0%
Net Profit Margin
-207.62%
↓ 188.2%
Q3 FY23Q/Q Change
Revenue
17.3M
↓ 19.31%
Net Income
1.2M
↓ 102.78%
Net Profit Margin
7.14%
↑ 214.76%
Q4 FY23Q/Q Change
Revenue
18.0M
↑ 3.8%
Net Income
-8.3M
↓ 769.77%
Net Profit Margin
-46.09%
↓ 53.23%
FY19Y/Y Change
Total Assets
1.2M
-
Total Liabilities
2.5M
-
FY20Y/Y Change
Total Assets
19.5M
↑ 1558.49%
Total Liabilities
3.2M
↑ 29.21%
FY21Y/Y Change
Total Assets
85.5M
↑ 339.44%
Total Liabilities
8.5M
↑ 166.65%
FY22Y/Y Change
Total Assets
81.0M
↓ 5.26%
Total Liabilities
24.6M
↑ 187.83%
FY23Y/Y Change
Total Assets
23.6M
↓ 70.83%
Total Liabilities
17.2M
↓ 29.92%
Q3 FY22Q/Q Change
Total Assets
73.1M
↓ 7.5%
Total Liabilities
19.0M
↑ 14.27%
Q4 FY22Q/Q Change
Total Assets
81.0M
↑ 10.74%
Total Liabilities
24.6M
↑ 29.56%
Q1 FY23Q/Q Change
Total Assets
77.0M
↓ 4.87%
Total Liabilities
23.4M
↓ 4.67%
Q2 FY23Q/Q Change
Total Assets
30.5M
↓ 60.44%
Total Liabilities
20.3M
↓ 13.56%
Q3 FY23Q/Q Change
Total Assets
31.6M
↑ 3.68%
Total Liabilities
18.5M
↓ 8.76%
Q4 FY23Q/Q Change
Total Assets
23.6M
↓ 25.23%
Total Liabilities
17.2M
↓ 6.8%
FY19Y/Y Change
Operating Cash Flow
-453.8K
-
Investing Cash Flow
-517.2K
-
Financing Cash Flow
1.0M
-
FY20Y/Y Change
Operating Cash Flow
-8.4M
↑ 1755.58%
Investing Cash Flow
-2.2M
↑ 318.41%
Financing Cash Flow
25.8M
↑ 2469.62%
FY21Y/Y Change
Operating Cash Flow
-20.6M
↑ 145.2%
Investing Cash Flow
-14.6M
↑ 572.37%
Financing Cash Flow
58.1M
↑ 125.08%
Q3 FY22Q/Q Change
Operating Cash Flow
-3.3M
↓ 14.61%
Investing Cash Flow
-157.0K
↓ 98.06%
Financing Cash Flow
-415.0K
↓ 41.47%
Q4 FY22Q/Q Change
Operating Cash Flow
-2.1M
↓ 37.21%
Investing Cash Flow
-102.0K
↓ 35.03%
Financing Cash Flow
5.3M
↓ 1387.71%
Q1 FY23Q/Q Change
Operating Cash Flow
-4.3M
↑ 105.61%
Investing Cash Flow
-102.0K
↑ 0.0%
Financing Cash Flow
-19.0K
↓ 100.36%

Technicals Summary

Sell

Neutral

Buy

Flora Growth Corp is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Flora Growth Corp
Flora Growth Corp
-25.24%
117.39%
-63.33%
-98.39%
-98.39%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
-2.41%
27.65%
34.11%
39.49%
77.94%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
-0.12%
5.13%
-5.51%
13.36%
13.36%
Zoetis Inc.
Zoetis Inc.
-7.43%
-2.98%
-11.32%
-9.68%
48.39%
Viatris Inc.
Viatris Inc.
-1.12%
27.59%
26.04%
-15.35%
-29.8%
Catalent, Inc.
Catalent, Inc.
-0.82%
42.09%
27.6%
-51.77%
23.97%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Flora Growth Corp
Flora Growth Corp
NA
NA
NA
-0.5
-1.49
-0.13
NA
0.72
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
56.26
56.26
0.44
4.78
0.13
0.09
NA
22.61
Haleon Plc Spon Ads
Haleon Plc Spon Ads
29.82
29.82
1.69
0.45
0.07
0.04
0.03
1.8
Zoetis Inc.
Zoetis Inc.
29.5
29.5
2.58
5.8
0.5
0.13
0.01
10.9
Viatris Inc.
Viatris Inc.
231.0
231.0
NA
2.78
0.0
0.03
0.04
17.05
Catalent, Inc.
Catalent, Inc.
211.02
NA
2.06
0.48
-0.3
-0.01
NA
20.41
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Flora Growth Corp
Flora Growth Corp
Buy
$16.5M
-98.39%
NA
-74.98%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$14.1B
77.94%
56.26
13.23%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$38.1B
13.36%
29.82
9.28%
Zoetis Inc.
Zoetis Inc.
Buy
$68.3B
48.39%
29.5
27.43%
Viatris Inc.
Viatris Inc.
Hold
$13.7B
-29.8%
231.0
0.35%
Catalent, Inc.
Catalent, Inc.
Hold
$10.1B
23.97%
211.02
-31.77%

Institutional Holdings

  • Mirae Asset Global Investments (Korea) Co Ltd

    12.04%

  • Renaissance Technologies Corp

    0.74%

  • Geode Capital Management, LLC

    0.44%

  • Vanguard Group Inc

    0.21%

  • XTX Topco Ltd

    0.15%

  • Tower Research Capital LLC

    0.08%

Corporate Announcements

  • Flora Growth Corp Earnings

    Flora Growth Corp’s price-to-earnings ratio stands at None

    Read More

Company Information

at flora growth corp. (flora), we are building the world’s largest and lowest cost vertically-integrated producer of organic cannabis and pharmaceutical-grade medical products as well as cbd-based consumer products.

Organization
Flora Growth Corp
Employees
97
CEO
Mr. Clifford A. Starke
Industry
Healthcare

Discover More

FAQs